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Abstract
Engineered neural stem cells (NSCs) are a promising approach to treating glioblastoma (GBM). 
The ideal NSC drug carrier for clinical use should be easily isolated and autologous to avoid 
immune rejection. We transdifferentiated (TD) human fibroblasts into tumor-homing early-stage 
induced NSCs (h-iNSCTE), engineered them to express optical reporters and different therapeutic 
gene products, and assessed the tumor-homing migration and therapeutic efficacy of cytotoxic h-
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iNSCTE in patient-derived GBM models of surgical and nonsurgical disease. Molecular and 
functional analysis revealed that our single-factor SOX2 TD strategy converted human skin 
fibroblasts into h-iNSCTE that were nestin+ and expressed pathways associated with tumor-
homing migration in 4 days. Time-lapse motion analysis showed that h-iNSCTE rapidly migrated 
to human GBM cells and penetrated human GBM spheroids, a process inhibited by blockade of 
CXCR4. Serial imaging showed that h-iNSCTE delivery of the proapoptotic agent tumor necrosis 
factor–a–related apoptosis-inducing ligand (TRAIL) reduced the size of solid human GBM 
xenografts 250-fold in 3 weeks and prolonged median survival from 22 to 49 days. Additionally, 
h-iNSCTE thymidine kinase/ganciclovir enzyme/prodrug therapy (h-iNSCTE–TK) reduced the size 
of patient-derived GBM xenografts 20-fold and extended survival from 32 to 62 days. Mimicking 
clinical NSC therapy, h-iNSCTE–TK therapy delivered into the postoperative surgical resection 
cavity delayed the regrowth of residual GBMs threefold and prolonged survival from 46 to 60 
days. These results suggest that TD of human skin into h-iNSCTE is a platform for creating tumor-
homing cytotoxic cell therapies for cancer, where the potential to avoid carrier rejection could 
maximize treatment durability in human trials.
INTRODUCTION
Cancers of the brain remain among the most challenging tumors to treat (1). More than 
10,000 patients are diagnosed each year with glioblastoma (GBM), the most common 
primary brain tumor. GBM is treated with surgery and chemoradiation therapy, but the 
disease is universally fatal. Average time to recurrence is only 6 months, and average 
survival for GBM patients is 12 to 15 months. One of the most promising strategies to treat 
GBM is engineered neural stem cells (NSCs) (2). NSCs naturally migrate to solid and 
diffuse GBM deposits in response to chemotactic signals released by the cancer cells (3–6). 
When engineered with different cytotoxic agents, NSC therapy reduces GBM xenografts’ 
volumes by 70 to 90% and extends the survival of tumor-bearing mice (2, 3, 7–10). On the 
strength of these preclinical studies, the first phase 1 trial of cytotoxic NSC therapy for 
GBM was recently completed (identifier: ). Allogeneic NSCs that convert 5-fluorocytosine 
to 5-fluorouracil were delivered into the walls of the postsurgical resection cavity and found 
to be well tolerated in patients. Two additional phase 1 trials have now been launched to 
further develop this promising approach (identifiers: and ). Although preclinical and clinical 
testing has relied heavily on allogeneic NSCs, autologous patient-derived NSC therapies 
could be highly advantageous in clinical use. The ability of autologous NSC therapy to avoid 
immune rejection not only would eliminate the complications of immunosuppressive 
regimens but also could prolong cytotoxic NSC persistence to increase both GBM killing 
and treatment durability. Unfortunately, isolation of autologous NSCs for GBM therapy 
remains a major challenge (11).
Reprogramming a patient’s own somatic cells to create autologous cell therapies has opened 
therapeutic possibilities for cell-based central nervous system (CNS) treatment (12). 
Transdifferentiation (TD), in particular, is critically important for cell transplant therapies 
(13). TD directly converts fully differentiated somatic cells into somatic cells of a different 
type. This is accomplished without passing through an undifferentiated pluripotent state and 
increases the rate and efficiency of conversion as well as the in vivo safety (14–19). Thus, 
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TD cells are ideal for cell replacement, and they avoid immune surveillance because they are 
the patient’s own cells (20). After the initial reports of TD in mouse cells (14–17), 
subsequent discoveries showed that TD can be used to create human NSCs, referred to as 
induced NSCs (h-iNSCs) (18, 19). This finding suggests that TD can be used to create 
patientspecific therapies for CNS disorders. However, the efficacy of TD-derived h-iNSC 
therapy for cancer has not been explored.
As an initial step toward developing an easily translatable personalized h-iNSC therapy for 
GBM, we provide evidence that TD-derived h-iNSC therapies can serve as tumor-homing 
drug carriers that inhibit the progression of GBM. Time is a priority for GBM patient 
therapy, and our TD strategy is capable of rapidly converting human skin fibroblasts into 
early-stage tumor-homing iNSCs (h-iNSCTE)in only 4 days, as confirmed by molecular and 
functional profiling of the cells. We then engineered h-iNSCTE with optical reporters and 
cytotoxic agents and investigated the fate and tumor-specific homing of cytotoxic h-iNSCTE 
using a combination of real-time molecular imaging, three-dimensional (3D) cell culture, 
and mouse models of human GBM. Next, we used therapeutic h-iNSCTE engineered with 
the secreted proapoptotic protein tumor necrosis factor–α–related apoptosisinducing ligand 
(TRAIL) or enzyme/prodrug therapy and mouse models of both established orthotopic 
patient-derived tumor xenografts and diffuse postsurgical residual disease to investigate the 
efficacy of h-iNSCTE therapy for GBM.
RESULTS
h-iNSC therapies for cancer
To create h-iNSC therapies for cancer treatment, we developed a TD strategy that is faster 
than previous reports to be compatible with the time frame for clinical GBM patient care 
(outlined in Fig. 1A) (18, 19). Normal human fibroblasts were transduced with SOX2 
(SOX2/NHF) and cultured in NSC-inducing medium (Fig. 1B). Within 48 hours, the 
morphology of the SOX2/NHF changed, the cells formed neurospheres, and expression of 
the NSC marker nestin was detected and remained constant through day 10 (Fig. 1, B and 
C). Genetic engineering of the SOX2/NHF with lentivirus encoding green fluorescent 
protein (GFP) and firefly luciferase resulted in robust GFP expression. The cells retained 
high nestin expression and differentiated into GFAP+ astrocytes and TUJ-1+ neurons but 
lacked the pluripotency markers TRA-1–60 and OCT-4 (Fig. 1D). This was confirmed by 
real-time polymerase chain reaction (RT-PCR) analysis, which showed that the SOX2/NHF 
cells expressed the NSC marker nestin at levels ninefold higher than parental fibroblasts and 
threefold higher than human induced pluripotent stem cells (h-iPSCs) (Fig. 1E). SOX2 
expression was high in both SOX2/NHF and h-iPSCs because SOX2 overexpression was 
used to generate both cell lines. Unlike h-iPSCs, SOX2/NHF did not have high expression of 
the pluripotency markers nanog or OCT-4. On the basis of these morphologic, genetic, and 
functional assays, we concluded that TD-converted SOX2/NHF were h-iNSCs.
A recent study revealed that a continuum of genetic changes occurs because fibroblasts are 
directly reprogrammed into iNSCs (21). We performed RNA sequencing (RNA-seq) to 
investigate the expression profile of h-iNSCs with a focus on key biologic parameters of 
tumor-homing cell migration. Differential expression analysis revealed substantial 
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transcriptional changes in h-iNSCs compared to the parental fibroblasts (Fig. 2, A and B), 
with 2810 genes up-regulated and 2660 genes down-regulated at day 5 after induction. 
Tumor-homing migration is one of the most critical aspects of stem cell therapy for cancer, 
unlike regenerative medicine. When we focused on genes that fall into the category of cell 
migration (22–24), we found that they were enhanced in both h-iNSCs and control brain-
derived NSCs, suggesting that h-iNSCs have tumor-homing properties displayed by brain-
derived NSCs (Fig. 2C). Additionally, genes associated with neuron development, ion 
transport, organ morphogenesis, and immune response were activated in both h-iNSC and 
NSC. Previously, similar pathway expression was reported in early-stage iNSCs because 
they transitioned from fibroblasts to mature iNSCs that closely resembled brain-derived 
NSCs (21). When we analyzed pathways related to tumor-homing migration, we found that 
CXCR4, FLT1, HIF1A, and ANXA2 all showed changes in expression as fibroblasts 
converted to iNSCs (Fig. 2, D and E). Together, these results suggest that our rapid TD 
process generates early-stage iNSCs whose expression of tumor-homing pathways makes 
them suitable carriers for cancer treatment. To avoid confusion with previous studies, these 
cells will be referred to as h-iNSCTE.
Assessing the tumor-homing properties of human iNSCs
Tumor-homing migration is one of the most distinctive and beneficial aspects of wild-type 
NSC therapy. Because expression analysis revealed that the pathways related to tumor-
homing are increased in these cells, we next used real-time motion analysis to investigate the 
tumor-tropic nature of skin-derived h-iNSCTE. h-iNSCTE–mC-FL were seeded adjacent to 
GFP+ human GBM cells. Fluorescent timelapse images showed that h-iNSCTE rapidly 
migrated toward the human GBM cells, with the leading edge covering the 500-mm gap in 
22 hours (Fig. 3A and movie S1). Analyzing the migratory path of single cells confirmed the 
directional migration of h-iNSCTE toward the GBM cells (Fig. 3C and movies S2 and S3). 
This tumor-directed migration was specific to the h-iNSCTE, whereas the parental NHF 
exhibited nondirected random migration with minimal displacement toward the GBM cells 
(Fig. 3, B to D, and movies S4 to S6). h-iNSCTE migrated in a more directed pattern, 
displaying a directionality index of 0.65 compared to NHF that displayed a more random 
migration index of 0.28 (Fig. 3D). h-iNSCTE also migrated a longer Euclidean distance than 
NHF (340 μm versus 200 μm) (Fig. 3E). Last, we mimicked the in vivo migration of h-
iNSCTE into established GBM foci using 3D cell spheroid cultures. h-iNSCTE–mC-FL 
spheroids were cocultured with GFP+ GBM spheroids, and both cell types were levitated 
using magnetic force. h-iNSCTE were found to penetrate the GBM spheroids within hours of 
seeding (Fig. 3F) and continued migrating into the core of the GBM spheroid through 7 days 
of culture. CXCR4 is one of the most wellestablished mediators of tumoritropic homing (22, 
24). RT-PCR analysis confirmed that CXCR4 expression was increased 4.3-fold after 
fibroblasts were converted into h-iNSCTE (Fig. 3G). Further, pretreatment of h-iNSCTE with 
CXCR4-blocking antibodies markedly reduced the tumor-homing capacity of the cells 
compared to untreated cells in our coculture migration assays (Fig. 3, H to J, and movies S7 
and S8). Together, these observations support the conclusion that h-iNSCTE have 
tumoritropic properties that allow them to migrate to GBM cells.
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h-iNSCTE therapy of human GBM xenografts in mice
To monitor h-iNSCTE in vivo, we engineered the cells to express the optical reporters 
mCherry and firefly luciferase (h-iNSCTE–mC-FL). We found that the genetic engineering 
had minimal effect on proliferation because h-iNSCTE and h-iNSCTE–mC-FL grew at 
similar rates (Fig. 4A). To study the persistence of h-iNSCTE in the brain, we stereotactically 
implanted h-iNSCTE–mC-FL into the brains of mice. Real-time noninvasive imaging 
showed that h-iNSCTE persisted through 21 days but were gradually cleared (Fig. 4B). 
Revealing the fate of the h-iNSCTE, postmortem immunohistochemistry showed that 
numerous h-iNSCTE–mC-FL expressed the NSC marker nestin (Fig. 4C). A portion of h-
iNSCTE stained positive for the neuronal marker TUJ-1 (Fig. 4C), but minimal staining was 
detected for the astrocyte marker GFAP (Fig. 4C). No OCT-4 and TRA-1–60 expression was 
detected, indicating that the transplanted h-iNSCTE do not express markers of a potentially 
carcinogenic pluripotent intermediate in vivo. Together, these findings suggest that the h-
iNSCTE survive in the murine brain, do not exhibit malignant transformation, and express 
markers of NSCs as well as potentially differentiate into cells of a neural lineage.
We first tested the efficacy of h-iNSCTE delivery of a secreted cytotoxic agent for the 
treatment of solid GBM. h-iNSCTE were engineered to express a secreted variant of the 
proapoptotic molecule TRAIL (h-iNSCTE–sTR; Fig. 5, A and B). The anti-GBM effects of 
TRAIL are well established, and the agent has been extensively used in cell-based GBM 
therapy (3, 8, 25, 26). h-iNSCTE–sTR or control iNSC–GFP-RL were mixed at different 
ratios with mC-FL+ human GBM cells in 3D culture for 48 hours. Fluorescence imaging and 
bioluminescence imaging (BLI) of GBM cell volumes showed that h-iNSCTE–sTR markedly 
reduced the viability of 3D GBM spheroids compared to control-treated tumors in a dose-
dependent pattern (Fig. 5C).
To test the efficacy of h-iNSCTE–sTR–based therapy against solid GBM in vivo, we 
implanted human U87 GBM cells expressing mC-FL with h-iNSCTE–sTR or control h-
iNSCTE–GFP (Fig. 5D) into the brain parenchyma of mice. Serial BLI of tumor volumes 
showed that h-iNSCTE–sTR treatment inhibited tumor growth by day 3, resulting in GBM 
volumes that were 50-fold smaller than in control animals by day 24 (Fig. 5, E and F). 
Survival analysis showed that h-iNSCTE–sTR– treated animals survived an average of 51 
days, whereas control animal succumbed to GBM in only 25 days (Fig. 5G). Postmortem 
analysis showed the h-iNSCTE–sTR staining positive for TRAIL 2 weeks after implantation. 
Additionally, the h-iNSCTE–sTR in the GBM stained positive for nestin and TUJ-1 but were 
negative for GFAP and pluripotency markers OCT-4 and TRA-1–60 (Fig. 5H). These data 
show that h-iNSCTE delivery of a secreted cytotoxic agent inhibits the growth of solid GBM 
and prolongs the survival of tumor-bearing animals.
We next explored the efficacy of h-iNSCTE prodrug/enzyme therapy against human patient–
derived GBMs that more accurately mimics the clinical treatment of the disease (9). We 
engineered h-iNSCTE with a bifunctional reporter including red fluorescent protein (RFP) 
and thymidine kinase (h-iNSCTE–TK). Cell viability assays showed that mixing (Fig. 6, A, 
B, and E) or side-by-side culturing (Fig. 6, C to E) of h-iNSCTE–TK with GBM4 patient–
derived CD133+ human GBM–initiating cells expressing GFP and FL (GBM4–GFP-FL) 
markedly reduced tumorspheroid viability compared to control-treated tumor spheroids after 
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the addition of the ganciclovir (GCV) prodrug. h-iNSCTE–TK+GCV killing of the 
established GBM spheroids was slower than in cell mixtures, likely because the therapeutic 
cells were not evenly distributed throughout the tumor spheroid as in the mixed model (Fig. 
6E).
We next determined the efficacy of h-iNSCTE–TK therapy against established GBM4 in 
vivo. GBM4–GFP-FL cells were implanted into the brain parenchyma of mice. Three days 
later, h-iNSCTE–TK were injected into the established tumors, and GCV or saline was 
administered to the animals (Fig. 6F). Serial BLI showed that h-iNSCTE–TK+GCV–treated 
tumors were 20-fold smaller than control 28 days after injection (Fig. 6G). The treatment 
significantly (P = 0.0018) extended the median survival of tumor-bearing mice (GCV, 67 
days; control, 37 days; Fig. 6H). Fluorescent imaging of postmortem tissue sections verified 
the reduction in tumor volumes by h-iNSCTE–TK therapy (Fig. 6, I and J). Large tumors 
were present in the brains of control-treated animals, yet only a few residual cells were 
detected in h-iNSCTE–TK+GCV–treated mice. Together, these results show that h-iNSCTE–
TK prodrug/enzyme therapy has therapeutic effects against patient-derived GBM and 
markedly prolongs the survival of tumor-bearing mice.
Intracavity h-iNSCTE prodrug/enzyme treatment of postsurgical minimal patient-derived 
GBM in mice
Surgical resection is part of the clinical standard of care for GBM patients (1). We next used 
our mouse models of GBM resection/recurrence and synthetic extracellular matrix 
encapsulation (sECM) strategies to determine the efficacy of h-iNSCTE–TK therapy for 
surgically resected GBMs (26, 27). To investigate the migration of h-iNSCTE–TK 
encapsulated in sECM, we performed 3D cultures of the encapsulated h-iNSCTE with GFP-
FL+ GBM8 spheroids (patient-derived CD133+ human GBM–initiating cells; Fig. 7A). We 
found that mCherry+ h-iNSCTE migrated from the sECM and populated GFP+ GBM8 
spheroids within 3 days (Fig. 7B). 3D coculture assays showed that sECM/h-iNSCTE–TK 
therapy markedly reduced the viability of GBM8 spheroids after addition of GCV (Fig. 7C).
To mimic h-iNSCTE therapy for human patients with surgically resected GBM, invasive 
patient-derived GBM8 cells were implanted into the brain parenchyma of mice (Fig. 7D). 
Ten days later, the established tumors were surgically resected. h-iNSCTE–TK were 
encapsulated in sECM and transplanted into the surgical resection cavity, and mice were 
treated with GCV or saline. Serial BLI showed that h-iNSCTE–TK+GCV therapy attenuated 
the regrowth of GBM8 tumors such that residual tumors were 3.5-fold smaller in the treated 
animals compared to control 14 days after h-iNSCTE–TK implantation (Fig. 7E). h-iNSCTE–
TK+GCV therapy also extended median survival, with h-iNSCTE–TK+GCV–treated animals 
surviving an average of 60 days compared to 46 days in control-treated mice (Fig. 7F).
DISCUSSION
Cytotoxic NSC therapy for GBM recently entered phase 1 clinical patient testing on the 
strength of preclinical studies (9). Here, we provide evidence that human fibroblast–derived 
h-iNSCTE are tumor-homing drug carriers. Using clinically relevant mouse models and 
therapeutic agents, we show that h-iNSCTE therapy regressed solid GBM and suppressed 
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recurrence of postsurgical GBM. These results position h-iNSCTE technology as a feasible 
approach to eventual routine autologous therapy without the need for invasive brain biopsy 
or lifelong immunosuppressive treatment.
We sought to use next-generation cellular reprogramming to generate easily isolated and 
autologous NSC therapies for cancer therapy. In the clinical setting, the potential of 
autologous carriers, such as h-iNSCTE, to avoid immune rejection could provide therapeutic 
advantages over allogeneic NSC therapies currently used in clinical trials. Studies using 
reprogramming technology for cancer therapy are limited; however, initial studies harnessed 
iPSC technology to establish proof of concept. Yamazoe et al. showed that mouse NSCs 
derived by the multistage iPSC process have the capacity to home to GBM both in vitro and 
in vivo (28). Yang et al. used human iPSC-NSC and showed that the tumorhoming migration 
of these cells is not limited to the brain because they could seek out metastatic breast cancer 
foci when infused intravenously (29). Zhu et al. extended these findings into therapy, 
showing that iPSC-NSC delivery of prodrug/enzyme therapy slowed progression of 
metastatic breast cancer xenografts, and both killing and safety were improved by additional 
modification with the vesicular stomatitis virus glycoprotein (30). Our approach uses cells 
created by TD, where fibroblasts are directly converted into iNSCs. The rapid generation of 
cells in this single-step process is essential for GBM treatment because patients have only 
months to live (31). Further, elimination of the potentially tumorigenic iPSC and embryoid 
body stages should help ensure that h-iNSCTE/iNSCs are non–tumor-forming in vivo. The 
current study explores iNSC derived from human fibroblasts for cancer therapy. To further 
maximize the translational relevancy of our study, we used a SOX2 TD strategy that both 
eliminated the need for feeder cells and increased the rate of h-iNSCTE generation compared 
to established TD methods (19). In vitro, forced differentiation produced h-iNSCTE that 
differentiated into both astrocytes and neurons and did not express pluripotency markers. In 
vivo, the h-iNSCTE survived through 3 weeks and remained positive for nestin or TUJ-1 but 
did not express OCT-4 or TRA-1–60. The h-iNSCTE were also potent drug delivery vehicles, 
rapidly migrating to GBM cells or spheroids and delivering cytotoxic gene products to 
reduce GBM progression.
We found that h-iNSCTE share key similarities with traditional brain-derived NSCs used for 
cancer therapy (4, 6, 9, 32, 33). For studies focusing on the use of NSC/iNSCs for cancer 
treatment, the ability of the cells to seek out cancer foci and deliver cytotoxic agents is 
essential (2, 34). Although the focus of our study was on the development of iNSCs for 
cancer therapy rather than regenerative medicine, we found that h-iNSCTE had high 
expression of nestin and differentiated into appropriate neural lineages in vitro and in vivo, a 
key attribute of brain-derived NSCs. Our genetic analysis revealed numerous similarities in 
the expression profiles of the two cell types. Critical for use as drug carriers, h-iNSCTE 
showed high expression of pathways implicated in mediating the tumor-homing capacity of 
wild-type NSCs. In particular, RT-PCR analysis showed that CXCR4, the most well-
established mediator of tumor homing in brain-derived NSCs (22, 24), was markedly up-
regulated as fibroblasts were converted into h-iNSCTE. Functional studies showed that h-
iNSCTE rapidly migrated to human GBM cells and penetrated into GBM spheroids. We and 
others previously reported the ability of human brain–derived NSCs to migrate to GBM, 
where they also penetrated the borders of the established tumor (3–5). Functional assays also 
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identified CXCR4 as a key mediator of h-iNSCTE tumoritropic homing, in agreement with 
studies demonstrating a central role for this receptor in the tumor-homing migration of 
brain-derived NSC drug carriers (24). Exploring further similarities to brain-derived NSC 
therapies, we found that the h-iNSCTE were gradually cleared over 14 days in vivo, with 
most of the cells having cleared by day 25. This persistence was very similar to our previous 
findings using human brain–derived NSCs delivered in the context of GBM (4). 
Additionally, both h-iNSCTE and wild-type NSCs remained predominantly nestin+ after 
implantation. We believe that these data validate h-iNSCTE as tumor-homing drug carriers 
for use as anticancer therapies. The rapid generation of h-iNSCTE should enable scale-up 
and generation of clinical numbers of therapeutic cells within the small therapeutic window 
required for patient trials. Further studies will be required to determine the ability of h-
iNSCTE to seek out other solid cancer types, as well as the potential to accumulate 
selectively in tumors after intravenous infusion.
We used h-iNSCTE engineered with two different cytotoxic agents. TRAIL is a secreted 
proapoptotic agent that has been used extensively in preclinical NSC-based GBM therapy (3, 
8, 35, 36). We found that h-iNSCTE–sTR treatment reduced the viability of U87 GBM 
spheroids in 3D cultures and markedly reduced tumor volumes in vivo. Clinical NSC 
therapy for GBM uses a prodrug/enzyme approach (9). Therefore, we also used h-iNSCTE–
TK+GCV therapy. In this approach, nontoxic GCV is phosphorylated by TK in the h-
iNSCTE and converted to a toxic compound that diffuses into neighboring tumor cells to 
induce death (37). Our data showed that h-iNSCTE–TK could kill solid patient-derived 
GBM4 spheroids. The killing was slower than when h-iNSCTE–TK were mixed throughout 
the GBM spheroid but closely matched the in vivo killing kinetics when h-iNSCTE–TK were 
injected into established GBM4 tumors in the brains of mice. These data demonstrate that h-
iNSCTE prodrug/enzyme therapy is a feasible approach to reduce GBM volumes. The 
current standard of care for GBM consists of surgery, temozolomide (TMZ), and radiation. 
This approach was adopted in 2005 after the publication of the landmark phase 3 trial 
showing that inclusion of TMZ with fractionated radiation and surgery extended median 
survival of newly diagnosed GBM patients from 12.1 to 14.6 months (38). Numerous 
preclinical studies have investigated the impact of each clinical treatment independently. 
Many of these studies used established cell lines, allowing for direct comparison to the U87 
used in our study. In previous studies investigating the impact of radiation on U87 growth, it 
was reported that 8 Gy extends survival of U87-bearing mice from about 29 to 38 days (39). 
Investigating TMZ, a meta-analysis of more than 2443 mice showed an average increase in 
median survival of 1.88-fold and average reduction in tumor volumes of 50% (40, 41). Data 
specifically on U87 were similar, showing reductions in tumor volume of just greater than 
50% and increased survival around 1.7-fold. Data on the impact of surgical resection are 
limited by the lack of preclinical models incorporating resection. We previously found that 
surgical debulking of U87 intracranial xenografts extended the survival from 25 to 32 days 
(26). Here, we found that h-iNSCTE therapy reduced U87 tumor volumes 250-fold at 3 
weeks after treatment and increased survival 2.23-fold. When compared to these reported 
preclinical studies using the clinical standard of care, our findings suggest that h-iNSCTE 
therapy could be an effective treatment option to improve care for GBM patients.
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Surgical resection is part of the clinical standard of care for GBM patients (1). Yet, solid 
GBM xenografts have been the standard model used to characterize GBM therapies (2). In 
our study, 3D culture systems show that both h-iNSCTE–TK spheroids and sECM-
encapsulated h-iNSCTE–TK killed patient-derived GBM spheroids in a time frame that 
closely mirrored the in vivo tumor response. Our results showed that h-iNSCTE–sTR 
treatment regressed solid U87 GBM xenografts in vivo and prolonged the survival of tumor-
bearing mice. h-iNSCTE–TK treatment had similar effects against established patient-
derived GBM4 xenografts. Using our image-guided model of GBM resection/recurrence in 
mice (27), we found that intracavity h-iNSCTE–TK treatment suppressed the regrowth of 
patient-derived GBM8 xenografts. Extensions in survival were not as pronounced in solid 
GBM treatment. The exact reason is unknown but could be due to the challenge of 
eradicating the highly invasive GBM8 tumor cells (42). Yet, our results demonstrate that 
cytotoxic h-iNSCTE treatment can inhibit the progression of solid tumors and recurrence of 
postsurgical patient-derived GBM xenografts.
NSC therapy for GBM is rapidly expanding in the clinic (9, 33). h-iNSCTE therapy could 
address the challenge of personalized NSC drug carriers that potentially limit allogeneic 
treatments currently under clinical testing. The effectiveness of stem cell–based cancer 
therapies is reliant on their ability to seek out distant cancer foci and function as in vivo drug 
pumps to deliver cytotoxic agents for extended durations. The prospects of personalized 
drug carriers, such as h-iNSCTE, to avoid immune rejection in patients suggest the potential 
for longer persistence in human patients compared to allogeneic therapies. This would, in 
turn, create a larger window during which the therapeutic cells could migrate, affording h-
iNSCTE the increased time required to track down invasive tumor spread at long distances 
from the resection cavity. This will be particularly important in clinical testing, where 
therapeutic cells will be required to track down invasive GBM foci on the scale of the human 
brain. The longer persistence should also prolong the duration of drug delivery, thus 
improving tumor kill and sustaining durable tumor suppression better than drug carriers that 
are rapidly cleared from the brain. Although data are limited, a previous study suggests that 
autologous cell implants generated by reprogramming do persist longer than allogeneic 
implants (43). Greater numbers of self-derived iPSC neurons were found to persist after 
transplant, cause only minor immune activation, and improve therapy compared to 
allogeneic transplant that resulted in activation of both microglia and leukocytes (43). 
Because our data support the conclusion that h-iNSCTE are tumor-homing cell carriers with 
anticancer efficacy, this sets the stage for future studies comparing the precise benefits of 
this approach over traditional allogeneic cell carriers as well as other delivery systems 
including nanoparticles, oncolytic viruses, and chemotherapeutic agents.
In conclusion, these studies provide evidence that cytotoxic h-iNSCTE are tumor-homing 
drug carriers that inhibit GBM progression in mouse models, which reflect the clinical 
scenario of GBM therapy. These findings should serve as a guide to design clinical trials 
where a patient’s own skin cells could be used to create cytotoxic drug carriers that are 
reimplanted into the patient to maximize tumor killing. This could have broad clinical 
impact, as cytotoxic NSC therapy is being explored for the treatment of metastatic (44), 
pediatric (45, 46), and peripheral cancer (47). The establishment of Good Manufacturing 
Practice facilities at numerous institutions and the entrance of reprogrammed cells into 
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human clinical trials support the feasibility of translating h-iNSCTE and related therapies 
into the clinical setting.
MATERIALS AND METHODS
Study design
This preclinical study was designed to explore the efficacy of h-iNSCTE as an approach to 
cancer therapy. We theorized that TD could be used to convert human skin fibroblasts into 
tumor-homing terapeutic iNSCs that could migrate to GBM cells and deliver therapeutic 
transgenes to inhibit pogression of the disease. We used multiple approaches to characterize 
the fate of tumoricidal h-iNSCTE, their tumor-homing capacity, and their anti-GBM 
properties. These approaches included assaying cell migration using real-time kinetic 
tracking of in vitro coculture assays as well as 3D cell culture models. Tumor killing was 
determined with therapeutic h-iNSCTE engineered with two different cytotoxic agents 
(TRAIL and TK/GCV) and tested in two different mouse models of GBM, where one model 
used orthotopic established GBMs and the other incorporated surgical tumor resection of 
patient-derived cancer lines. Animal numbers for each study are detailed in the relevant 
sections below. GBM volumes were determined using serial BLI. Mice were randomized 
into control and treatment groups based on the pretreatment BLI signal. Animals were 
monitored daily and euthanized at the onset of symptoms of debilitating disease, including 
weight loss, hunched posture, or impaired gait. We have included additional details on 
statistical analysis below.
Cell lines
U87 and 293T were purchased from the American Type Culture Collection. GBM8 and 
GBM4 were gifts from H. Wakimoto (Massachusetts General Hospital). Human fibroblasts 
were provided by W. Kauffman [University of North Carolina (UNC) School of Medicine]. 
All cells were grown as previously described (3, 42). Lentiviral vectors (LVs) encoding 
hTERT and SOX2 were purchased from Addgene. All complementary DNAs (cDNAs) were 
under the control of the tetracycline promoter.
Lentiviral vectors
In addition to the reprogramming vectors, the following LVs were used in this study: GFP 
fused to firefly luciferase (LV–GFP-FL), GFP fused to Renilla luciferase (LV–GFP-RL), 
mCherry protein fused to firefly luciferase (LV–mC-FL), a secreted variant of TRAIL (LV-
sTR), and an RFP thymidine kinase fusion (LV-TK; Life Technologies). GFP-RL and GFP-
FL were constructed by amplifying the cDNA encoding Renilla luciferase or firefly 
luciferase using the vectors luciferase-pcDNA3 and pAC-hRluc (Addgene), respectively. 
The restriction sites were incorporated in the primers, and the resulting fragment was 
digested with Bgl II and Sal I and ligated in-frame in Bgl II/Sal I–digested pEGFPC1 
(Clontech). The GFP-FL or GFP-RL fragments were digested with Age I (blunted) and Sal I 
and ligated into pTK402-digested (provided by T. Kafri, UNC Gene Therapy Center) Bam 
HI (blunted) and Xho I to create LV–GFP-FL or LV–GFP-RL. Similarly, mC-FL was 
created by amplifying the cDNA encoding firefly luciferase from luciferase-pcDNA3, 
ligating into Bgl II/Sal I–digested mCherry-C1 (Clontech), and ligating the mC-FL fragment 
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into pTK402 LV backbone using blunt/Xho I sites. To create LV-sTR, the cDNA sequence 
encoding sTR was PCR-amplified using custom-synthesized oligonucleotide templates 
(Invitrogen). The restriction sites were incorporated into the primers, and the resulting 
fragment was digested with Bam HI and Xho I and ligated in-frame into Bam HI/Xho I–
digested pLVX plasmid (a gift from S. Magness, UNC Department of Medicine). LV-sTR 
has IRES-GFP elements in the backbone as well as a cytomegalovirus-driven puromycin 
element. The bi-function TK virus was synthesized and cloned into the LV backbone by Life 
Technologies. All LV constructs were packaged as LV vectors in 293T cells using a helper 
virus–free packaging system as described previously (48). h-iNSCTE and GBM cells were 
transduced with LVs at varying multiplicity of infection by incubating virions in a culture 
medium containing protamine sulfate (5 μg/ml; Sigma), and cells were visualized for 
fluorescent protein expression by fluorescence microscopy.
h-iNSCTE generation
Human fibroblasts (200,000) were seeded in six-well plates and transduced with the LV 
cocktail containing hTERT and SOX2 in a medium containing protamine sulfate (5 μg/ml; 
Sigma). Two days after infection, the medium was changed to STEMdiff Neural Induction 
Medium (StemCell Technologies) containing doxycycline (10 μg/ml; Sigma). Medium was 
changed every 3 days. Neurosphere formation was induced by culturing in low-adherence 
flasks.
Cell viability and passage number
To assess the proliferation of modified and unmodified h-iNSCTE and h-iNSCTE expressing 
GFP-FL or sTR, the cells were seeded in 96-well plates. Cell viability was assessed 2 to 10 
days after seeding using CellTiter-Glo luminescent cell viability kit (Promega).
Immunohistochemistry and in vitro differentiation
To determine the effects of LV modification on h-iNSCTE differentiation, h-iNSCTE were 
transduced with LV–GFP-FL or LV-sTR. Engineered or unmodified cells (1 × 105 cells per 
well) were seeded on coverslips, fixed, permeabilized, and incubated for 1 hour with anti-
nestin polyclonal antibody (1:500; Millipore, ABD69). Cells were washed and incubated 
with the red secondary antibody (Biotium, 20038) for 1 hour. Cells were then washed, 
mounted, and imaged using fluorescence confocal microscopy. For differentiation, 
engineered or nontransduced h-iNSCTE (1 × 105 cells per well) were cultured for 12 days in 
stem cell medium depleted of doxycycline, epidermal growth factor, and fibroblast growth 
factor. Cells were then stained with antibodies directed against nestin, GFAP (1:250; 
Millipore, MAB3402), or TUJ-1 (1:1000; Sigma, T8578) and detected with a red secondary 
antibody (Biotium). Nuclei were counterstained with Hoechst 33342, and the results were 
analyzed using an FV 1200 laser confocal microscope (Olympus).
RNA-seq analyses
Total RNA was extracted from human fibroblast, h-iNSCTE, or brain-derived NSC cellular 
pellets using Qiagen RNeasy kits, followed by library preparation using a Stranded mRNA-
seq kit (Kapa Biosystems) according to the manufacturer’s instructions. High-throughput 
Bagó et al. Page 11













sequencing with 43–base pair paired-end reads was performed on NextSeq 500 using the 
Illumina High Output kit and analyzed as previously described (49, 50). QC-passed reads 
passing Illumina’s Purity Filter were aligned to the human reference genome (hg38) using 
MapSplice (51). The alignment profile was determined by Picard Tools v1.64 (http://
broadinstitute.github.io/ picard/). Aligned reads were sorted and indexed using SAMtools, 
translated to transcriptome coordinates, and then filtered for indels, large inserts, and zero 
mapping quality using UBU v1.0 (https://github.com/ mozack/ubu). Transcript abundance 
estimates for each sample were calculated using RSEM, an expectation-maximization 
algorithm (52) using the University of California Santa Cruz known gene transcript and gene 
definitions. Before visualization, raw RSEM read counts for all RNA-seq samples were 
normalized to the overall upper quartile (53). PCA, cluster analysis, differential expression 
testing with DESeq2 (54), and plotting of these results were performed in R 3.2.1.
h-iNSCTE survival and fate in vivo
To determine the survival of h-iNSCTE in vivo, h-iNSCTE expressing mC-FL (7.5 × 105 cells 
per mouse) were suspended in phosphatebuffered saline (PBS) and implanted 
stereotactically into the right frontal lobe of mice (n = 7). h-iNSCTE survival was determined 
by serial BLI performed for 20 days using the IVIS In Vivo Imaging System. To determine 
the fate of h-iNSCTE at a cellular resolution, animals were sacrificed 14 to 21 days after 
implantation, and their brains were extracted and sectioned. Tissue sections were stained 
with antibodies against nestin, GFAP, TUJ-1, OCT-4, and TRA-1–60 and visualized using a 
secondary antibody labeled with CF 488.
Real-time PCR
To assess the expression of NESTIN, SOX2, NANOG, OCT-4, and CXCR4, RT-PCR 
analysis was performed at the UNC Animal Clinical Chemistry and Gene Expression core 
facility using validated primer/probe sets for each target gene. Analysis was performed on an 
ABI 7300/7500 system. Data are expressed relative to GAPDH controls.
In vivo BLI
To track h-iNSCTE fate or tumor progression, serial BLI was performed as described (55, 
56). Briefly, mice were given an intraperitoneal injection of D-luciferin (4.5 mg per mouse 
in 150 μl of saline), and photon emission was assessed 5 min later using the IVIS Kinetic 
Optical System (PerkinElmer) with a 5-min acquisition time. Images were processed, and 
photon emission was quantified using the Living Image software (PerkinElmer). 
Additionally, mice were followed for survival over time.
3D tissue culture
3D levitation cell cultures were performed using the Bio-Assembler Kit (Nano3D 
Biosciences). Confluent six-well plates containing GBM or h-iNSCTE (5 × 105 cells per 
well) were treated with a magnetic nanoparticle assembly [NanoShuttle (NS), Nano3D 
Biosciences] overnight according to the manufacturer’s specifications. NS is a mixture of 
iron oxide and gold nanoparticles cross-linked with poly-L-lysine to promote cellular 
attachment. NS-treated GBM and h-iNSCTE were then detached with trypsin, resuspended, 
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and mixed at different ratios (0.5:1 and 1:1) in an ultralow attachment six-well plate in 2 ml 
of medium. A plastic lid containing six magnetic drivers (neodymium magnet with field 
strength of 50 G) was placed on top of the plate to levitate the cells to the air-liquid 
interface. Cells were levitated for 24 hours to create cell spheroids.
3D coculture viability assays
3D levitation culture was used in three separate in vitro cytotoxicity studies. h-iNSCTE 
expressing two different cytotoxic agents were used to treat one established GBM cell line 
(U87) and two patient-derived GBM lines (GBM4 and GBM8). To determine the 
cytotoxicity of TRAIL therapy, h-iNSCTE–sTR or h-iNSCTE–GFP spheroids were 
cocultured in suspension with U87–mC-FL spheroids at a ratio of 0.5:1 or 1:1 (iNSC/GBM). 
GBM spheroid viability was determined 48 hours later by FL imaging. To determine the 
cytotoxicity of prodrug enzyme therapy for patient-derived GBM4s, h-iNSCTE–TK 
spheroids were cocultured in suspension with patient-derived GBM4–GFP-FL spheroids or 
mixed with GBM cells before sphere formation. Spheroids were cultured with or without 
GCV (UNC hospitals), and GBM spheroid viability was determined 0, 2, 4, or 7 days after 
addition of the prodrug by FL imaging. To determine the cytotoxicity of the sECM-
encapsulated h-iNSCTE prodrug/enzyme therapy, h-iNSCTE–TK were encapsulated in 
sECM and placed in levitation culture with patient-derived GBM8–GFPFL spheroids. 
Viability was determined by FL imaging.
Real-time imaging and motion analysis
h-iNSCTE migration was assessed in 2D and 3D culture systems. To assess 2D migration, h-
iNSCTE expressing LV–mC-FL were seeded in microculture inserts in glass bottom 
microwell dishes (MatTek) using two-chamber cell culture inserts (Ibidi). U87 glioma cells 
expressing GFP were plated into the adjacent well (0.5-mm separation). Twenty-four hours 
after plating, cells were placed in a Viva View live-cell imaging system (Olympus) and 
allowed to equilibrate. The insert was removed, and cells were imaged at ×10 magnification 
every 20 min for 22 hours in six locations per well in three independent experiments. NIH 
Image with chemotaxis and manual tracking plug-ins was used to generate movies and 
determine both the total distance migrated and the directionality of migration. To perform 
the CXCR4-blocking study, h-iNSCTE were pretreated with anti-human CXCR4 monoclonal 
antibody (10 μg/ml; clone 12G5, R&D Systems) for 3 hours as described previously (57). 
2D migration was then assessed as described above. For 3D migration, h-iNSCTE migration 
to GBM spheroids was assessed in 3D culture systems by creating h-iNSCTE and GBM 
spheroids using levitation culture as described above. h-iNSCTE (red) and GBM (green) 
spheroids were cocultured in levitation systems. Real-time imaging was performed to 
visualize the penetration of GBM spheroids by h-iNSCTE in suspension.
Anti-GBM efficacy of h-iNSCTE therapy in vivo
Three different xenograft studies were performed to assess the anti-GBM effects of h-
iNSCTE engineered with two different cytotoxic agents. (i) To assess h-iNSCTE therapy in 
solid GBM, h-iNSCTE–sTR or iNSC–GFP-RL (5 × 105 cells per mouse) were 
stereotactically implanted into the right frontal lobe of mice (n = 7) together with U87–mC-
FL cells (5 × 105 cells per mouse). Therapeutic response was then determined by monitoring 
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tumor volumes with FL BLI. (ii) To assess h-iNSCTE prodrug/enzyme therapy for 
established patient-derived GBM, GBM4 cells expressing mC-FL (5 × 105 cells per mouse) 
were stereotactically implanted in the right frontal lobe of mice. Three days later, h-
iNSCTE–TK (n = 7, 5 × 105 cells per mouse) or h-iNSCTE–mRFP-hRL (n = 7, 7.5 × 105 
cells per mouse) were implanted into the established tumors. GCV was injected 
intraperitoneally daily for 2 weeks at a dose of 100 mg/kg. FL imaging was used to assess 
changes in tumor volume as described above, and mice were monitored for survival over 
time. (iii) To assess h-iNSCTE therapy in surgically resected GBM, patient-derived GBM8–
GFP-FL were harvested at 80% confluency and implanted stereotactically (5 × 105 cells) in 
the right frontal lobe: 2 mm lateral to the bregma and 0.5 mm from the dura. Ten days later, 
mice were immobilized on a stereotactic frame and placed under an Olympus MVX10 
microscope. Intraoperative microscopic white light, GFP, and RFP images were captured 
throughout the procedure using a Hamamatsu ORCA 03G charge-coupled device camera 
and software (Olympus). A midline incision was made in the skin above the skull, exposing 
the cranium of the mouse. The intracranial xenograft was identified using GFP fluorescence. 
A small portion of the skull covering the tumor was surgically removed using a bone drill 
and forceps, and the overlying dura was gently peeled back from the cortical surface to 
expose the tumor. Under GFP fluorescence, the GBM8–GFP-FL tumor was surgically 
excised using a combination of surgical dissection and aspiration, and images of GFP were 
continuously captured to assess accuracy of GFP-guided surgical resection. h-iNSCTE–TK 
or h-iNSCTE–mC-FL (5 × 105 cells) were encapsulated in hyaluronic sECM hydrogels 
(Sigma) and transplanted into the postoperative GBM cavity, and skin was closed using 
surgical glue. Mice were then administered GCV as described above. No procedure-related 
mortality was observed. GBM recurrence was visualized by FL imaging as described above, 
and mice were followed for survival.
Tissue processing
Immediately after the last imaging session, mice were sacrificed and perfused with formalin, 
and their brains were extracted. The tissue was immediately immersed in formalin. Coronal 
sections (30 μm) were generated using a vibrating microtome (Fisher). For nestin, GFAP, 
and TUJ-1 staining, sections were incubated for 1 hour in a blocking solution (0.3% bovine 
serum albumin, 8% goat serum, and 0.3% Triton X-100) at room temperature, followed by 
incubation at 4°C overnight with the following primary antibodies diluted in blocking 
solution: (i) anti-human nestin (Millipore), (ii) anti-GFAP (Millipore), (iii) anti-TRAIL 
(Prosci), and (iv) anti–TUJ-1 (Sigma). Sections were washed three times with PBS, 
incubated in the appropriate secondary antibody, and visualized using a confocal microscope 
(Olympus).
Study approval
All experimental protocols were approved by the Animal Care and Use Committees at the 
UNC at Chapel Hill, and care of the mice was in accordance with the standards set forth by 
the National Institutes of Health Guide for the Care and Use of Laboratory Animals, U.S. 
Department of Agriculture regulations, and the American Veterinary Medical Association.
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Data were analyzed by Student’s t test and paired t test when comparing two groups, and by 
one- and two-way ANOVA and repeated measures when comparing more than two groups. 
Data were expressed as means ± SEM, and differences were considered significant at P < 
0.05. Survival times of mouse groups were compared using log-rank test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Generation and characterization of diagnostic and therapeutic h-iNSCTE.
(A) Schematic depiction of the strategy used to create therapeutic and diagnostic variants of 
h-iNSCTE. Human fibroblasts were transduced with SOX2 and placed in NSC-inducing 
medium. After 4 days, the h-iNSCTE were expanded and transduced with optical reporters or 
tumoricidal transgenes. (B) White light and fluorescence photomicrographs of human 
fibroblasts and h-iNSCTE grown as monolayers and neurospheres or stained with antibodies 
against nestin (green). (C) Summary graph showing the expression of nestin over time at 
different days after induction of h-iNSCTE generation. (D) Immunofluorescence staining 
showing h-iNSCTE–GFP (green) expression of the NSC marker nestin (red) and GFAP+ 
astrocytes and TUJ-1+ neurons after differentiation by mitogen removal (staining shown in 
red). In contrast, no staining was observed for the pluripotency markers TRA-1–60 or 
OCT-4. Hoechst staining is shown in blue. Fluorescence images showing only the red (555 
nm) secondary antibody channel are shown in the bottom row. (E) RT-PCR analysis of 
nestin, SOX2, nanog, and OCT-4 expression in NHF, h-iNSCTE, and h-iPSCs. Data in (C) 
and (E) are shown as means ± SEM (error bars are from three to four independent 
experiments; n = 3 technical replicates). Scale bars, 200 μm. GAPDH, glyceraldehyde-3-
phosphate dehydrogenase.
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Fig. 2. Transcriptome changes as fibroblasts are converted into h-iNSCTE.
Differential expression analysis (A) and principal components analysis (PCA) (B) revealed 
differences in gene expression between parental human fibroblasts (HF) and h-iNSCTE. (C) 
Ontology analysis showing the differential gene expression between human fibroblasts, h-
iNSCTE, and brain-derived NSCs. Biological replicates are indicated by the numbers above 
each column. Gene ontology (GO) and example genes are shown in the red and blue boxes, 
respectively. (D) Heat map revealing the expression of six different tumor-homing migration 
genes across human fibroblasts, h-iNSCTE, and NSCs. Down- and up-regulated genes are 
indicated by red and green, respectively. (E) Box plots showing relative expression of tumor-
homing genes CXCR4, FLT1, HIF1A, and ANXA2. The box represents the 25th and 75th 
percentile, and the whiskers represent 1.5 × interquartile range (n = 3 technical replicates).
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Fig. 3. Engineered h-iNSCTE homing to GBM.
h-iNSCTE–mC-FL were seeded 500 μm away from mCherry-expressing human GBM cells 
and placed in a fluorescence incubator microscope. Time-lapse fluorescence images were 
captured every 20 min for 22 hours and used to construct movies that revealed the migration 
of h-iNSCTE to GBM in real time. (A and B) Summary images showing migration of h-
iNSCTE–mC-FL (red) (A) or parental human fibroblasts (B) toward U87–GFP-FL (green) at 
0 and 22 hours after plating. (C) Single-cell tracings depicting the paths of h-iNSCTE–mC-
FL or human fibroblast–directed migration toward GBM over 22 hours. Dashed line 
indicates the site of GBM seeding. (D and E) Summary graphs showing the directionality 
(D) and Euclidean distance (E) of h-iNSCTE or fibroblast migration toward GBM cells 
determined from the real-time motion analysis. **P = 0.00001, *P = 0.00049 by Student’s t 
test. (F) Fluorescence imaging showed the migration of h-iNSCTE–mC-FL (red) into U87 
spheroids (green) and their penetration toward the core of the tumor spheroid over time in 
3D levitation culture systems. (G) Summary graph of RT-PCR analysis showing the 
increased expression of CXCR4 in h-iNSCTE compared to fibroblasts. (H) Summary image 
and cell tracings showing the attenuated migration of h-iNSCTE after pretreatment with 
CXCR4-blocking antibody. (I and J) Summary graphs demonstrating a reduction in 
directional migration (I) (*P = 0.0000013 by Student’s t test) and Euclidean distance (J) (*P 
= 0.0000247 by Student’s t test) by h-iNSCTE treated with anti-CXCR4 antibodies. Data in 
(D), (E), (I), and (J) are means ± SEM of three independent experiments performed in 
triplicate. Scale bars, 200 μm.
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Fig. 4. In vivo characterization of h-iNSCTE transplanted into the mouse brain.
(A) Summary graph demonstrating the proliferation of unmodified h-iNSCTE and h-iNSCTE 
engineered to express mCherry/FL. No significant difference was found by two-way analysis 
of variance (ANOVA). (B and C) h-iNSCTE–mC-FL were implanted into the frontal lobes of 
mice, and serial BLI was used to monitor their persistence over 3 weeks. Summary graphs 
demonstrated that the h-iNSCTE persisted for 25 days, although they were gradually cleared 
(B). Immunofluorescence analysis of h-iNSCTE (red) 14 days after implantation into the 
brain showed nestin+ and TUJ-1+ cells, but minimal h-iNSCTE stained positive for the 
astrocyte maker GFAP or the pluripotency markers OCT-4 and TRA-1–60 (green) (C). Data 
in (A) and (B) are means ± SEM. (A) and (B) represent three different experiments 
performed in triplicate. Scale bars, 50 μm (C).
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Fig. 5. h-iNSCTE–mediated TRAIL therapy for solid GBM.
(A and B) Representative fluorescence photomicrographs depict h-iNSCTE engineered to 
secrete the proapoptotic agent TRAIL and grown in a monolayer (A) or as floating 
neurospheres (B). Expression of the internal ribosomal entry sites (IRES)–GFP element 
present in the construct is shown in green. (C) Images and summary data of 3D suspension 
cultures showing the viability of mCherry+ human U87 GBM spheroids (red) mixed with 
therapeutic h-iNSCTE–sTR or control cells at a ratio of 0.5:1 or 1:1. GBM spheroid viability 
was determined by BLI 48 hours after treatment. **P = 0.0169, *P = 0.038 by ANOVA. (D) 
h-iNSCTE–sTR therapy for solid GBM was performed by xenografting a mixture of h-
iNSCTE–sTR and U87 GBM cells into the brain parenchyma of severe combined 
immunodeficient mice. (E and F) Representative BLI (E) and summary data (F) 
demonstrating the inhibition of solid U87 GBM progression by h-iNSCTE–sTR therapy 
compared to control-treated mice. *P = 0.0044 by repeated-measures ANOVA. (G) Kaplan-
Meier survival curves demonstrating the extension in survival in h-iNSCTE–sTR–treated 
animals compared to h-iNSCTE–control. *P = 0.0067 by log-rank test. (H) Representative 
images demonstrating the expression of cytotoxic, differentiation, and pluripotency markers 
in h-iNSCTE–sTR after therapy. A subset of animals were sacrificed 14 days after therapy; 
brain sections were stained with antibodies against nestin, TRAIL, GFAP, TUJ-1, OCT-4, or 
TRA-1–60; and the colocalization between staining (magenta) and GFP+ h-iNSCTE–sTR 
(green) was visualized. Data in (C) are means ± SEM of three independent experiments 
performed in triplicate. Data in (F) are means ± SEM. Scale bars, 100 μm.
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Fig. 6. h-iNSCTE prodrug/enzyme therapy for human patient–derived GBMs.
(A to D) The antitumor effects of h-iNSCTE–TK therapy were determined in two different 
3D culture models. h-iNSCTE–TK (red) were either mixed GFP+ GBM4 patient-derived 
GBM cells (A and B) or seeded adjacent to established GBM4 spheroids (C and D), and 
GCV was added to initiate tumor killing. Serial fluorescence images showed the time-
dependent decrease in GBM4 spheroid volume by h-iNSCTE–TK+GCV therapy. (E) 
Summary graph demonstrating the reduction in GBM4 spheroid volume over 7 days by h-
iNSCTE–TK+GCV therapy either mixed or seeded adjacent to established spheroids. **P = 
0.0099, *P = 0.048 by ANOVA. (F to H) h-iNSCTE–TK therapy was assessed in vivo by 
injecting h-iNSCTE–TK cells into GBM4 tumors established 10 days earlier in the brains of 
mice (F). Serial BLI showed that the progression of GBM4 tumors was inhibited by h-
iNSCTE–TK+GCV therapy (G). *P = 0.0046 by repeated-measures ANOVA. (H) Kaplan-
Meier survival curves demonstrate the survival of mice bearing GBM4 tumors treated with 
h-iNSCTE–TK+GCV therapy or control h-iNSCTE. *P = 0.0018 by log-rank test. (I and J) 
Representative whole-brain and high-magnification images showing cell nuclei (blue), 
GBM4 (green), and h-iNSCTE–TK (red) distribution 21 days after delivering h-iNSCTE–
control (I) or h-iNSCTE–TK (J) into established GBM4 tumors. A large GBM4 tumor was 
present in the control h-iNSCTE–TK animals, and only a small GBM4 focus was detected in 
mice treated with h-iNSCTE–TK+GCV. Data in (E) are means ± SEM of three independent 
experiments performed in triplicate. Data in (G) are means ± SEM. Scale bars, 400 mm (B 
and D) and 200 μm (I and J).
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Fig. 7. Intracavity h-iNSCTE–TK therapy for surgically resected diffuse GBMs.
(A to C) 3D suspension cultures were used to assess the migration and antitumor efficacy of 
sECM-encapsulated h-iNSCTE–TK against patient-derived GBM8 spheroids (A). h-
iNSCTE–TK (red) encapsulated in sECM were found to migrate from the matrix and 
populate GBM8 spheroids 3 days after seeding (B). Summary data demonstrate that h-
iNSCTE–TK (red) encapsulated in sECM reduce the volume of GBM8 spheroids (green) 
after GCV treatment compared to spheroids treated without GCV (C). *P = 0.0016 by 
Student’s t test. (D to F) To mimic clinical h-iNSCTE therapy for surgically resected GBM, 
h-iNSCTE–TK were encapsulated in sECM and transplanted into the surgical cavity after 
resection of diffuse patient-derived GBM8 tumors expressing GFP-FL (D). Representative 
images and summary data for serial imaging demonstrating the inhibition of tumor 
recurrence after intracavity h-iNSCTE–TK therapy for postoperative minimal GBM8 tumors 
(E). *P = 0.0072 by repeated-measures ANOVA. Kaplan-Meier survival curves of mice that 
underwent surgical resection of diffuse patient-derived GBM8 tumor cells and were treated 
with control h-iNSCTE or h-iNSCTE–TK encapsulated in sECM and transplanted into the 
surgical cavity (F). *P = 0.0064 by log-rank test. Data in (C) are means ± SEM of three 
independent experiments performed in triplicate. Data in (E) are means ± SEM. Scale bars, 
200 μm.
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